[Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
From January 1993 to June 1998, 319 cases were histopathologically diagnosed as prostatic cancer. In 7 of the 319 cases (2.2%) transurethral resection of the prostate (TUR-P) had been performed and a diagnosis of benign prostatic hyperplasia had been made with the resected specimens. The interval between TUR-P and the diagnosis of prostatic cancer ranged from 22 months to 15 years. All the cases showed an elevation of the prostate specific antigen (PSA) value (6.4-399 ng/ml, Tandem-R: RIA) at the time of cancer diagnosis. In 2 cases, PSA was measured in cancer screening. The clinical stage was stage B1 in 2 cases, stage B2 in 2 and D2 in 3. Only one case had been regularly followed-up after TUR-P, in which cancer was diagnosed by needle biopsy 22 months after TUR-P, because of the sustained high PSA values. Since most of such patients have an advanced stage of prostate cancer, it is of importance to have periodical follow-up examinations after TUR-P. The measurement of PSA appears the most reliable means in this way.
Tanaka
Y
Y
Department of Urology, Saiseikai-Nara Hospital.
Aoyama
H
H
Momose
H
H
Ono
T
T
Samma
S
S
Tanaka
N
N
Akiyama
T
T
Tani
Y
Y
Masuda
Y
Y
Matsuki
H
H
Tani
M
M
Tanaka
M
M
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000601:surgery*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D013997:Time Factors; D020728:Transurethral Resection of Prostate
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen